Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked hemolytic enzymopathy affecting 3% of Southern Chinese males. Among 275 adult allogeneic hematopoietic stem cell transplantations (SCT), five cases (1.8%) each of donors and recipients were G6PD deficient. Among 107 autologous SCT, four patients (3.7%) were G6PD deficient. All subjects were male, except for two female patients with chronic myeloid leukemia (CML). The incidence of G6PD deficiency in female CML patients was significantly higher than the background female incidence (P = 0.004), but comparable with that in the males (P = 0.664). There was no significant hemolysis or delay in red cell engraftment, and all but one patient converted to donor G6PD screening status. One female patient achieved partial correction of her G6PD status and relapsed at 10 months. We suggest that G6PD deficiency should be tested for in all marrow donors and recipients in susceptible populations. From our data, there is a suggestion of increased clinical incidence of G6PD deficiency in female patients with multi-lineage clonal marrow disorders. Bone Marrow Transplantation (2002) 29, 399-402. DOI: 10.1038/sj/bmt/1703369 Keywords: glucose 6-phosphate dehydrogenase (G6PD) deficiency; bone marrow transplantation; female; clonal Hematopoietic stem cell transplanation (SCT) is the treatment of choice for many malignant and non-malignant marrow disorders. Successful allogeneic SCT results in complete donor chimerism in the lymphoid and myeloid lineages. Allogeneic SCT also corrects thalassemia 1 and enzymopathies (eg pyruvate kinase defiency).
zygotes although rare female cases may arise from extreme lyonization of the X chromosome in a heterozygote. Exposure to oxidative drugs may cause life-threatening hemolysis. In the BMT setting, trimethoprim-sulphmethosazole (cotrimoxazole), used frequently for Pneumocystis carinii prophylaxis, is the only major drug implicated. In HK, G6PD deficiency is routinely screened in all SCT donors and recipients. We surveyed the incidence and clinical course of BMT involving G6PD-deficient subjects in adult patients from 1995 to 2000.
Materials and methods
The study involved 275 allogeneic recipients (M:F = 164:111, median age = 40 years, range 16-56) and 107 autologous recipients (M:F = 55:52, median age = 43 years, range 17-67) SCT. Clinically significant G6PD deficiency was screened by fluorescent testing (detecting levels below 5.5 IU/g hemoglobin) and confirmed by enzyme quantification. 4 For choosing allogeneic HLA-identical donors (M:F = 142:133, median age = 41 years, range 8-65), normal G6PD results were preferred. For G6PD-deficient recipients who received allogeneic SCT from G6PD normal donors, cotrimoxazole was substituted for pentamidine as prophylaxis against pneumocystis only after stable engraftment with documented normal G6PD levels. For chronic myeloid leukemia (CML) cases, disease monitoring by reverse transcription polymerase chain reaction (RT-PCR), 5 fluorescence in situ hybridization (FISH) and cytogenetics was performed. 6 Chimerism study was performed by a PCR-based semi-quantitative microsatellite analysis. 7 The incidence of G6PD deficiency in male and female subgroups was compared against screening incidences from 0.43 million live-births in HK from 1984 to 1994. 
Results
Five allogeneic (1.8%) and four autologous (3.7%) SCT patients were G6PD deficient (Table 1) . Despite a bias in donor selection, G6PD deficient donors had to be used in five cases, including three donor-recipient pairs (male to male). There were only two female patients, both with CML ( Table 1 ). The median G6PD activity was 0.28 IU/g No. = case number; G6PD = glucose-6-phosphate dehydrogenase enzyme activity (IU/g hemoglobin); normal = activity Ͼ5.35; Platelet Ͼ25 = time in days for platelet count Ͼ25 × 10 9 /l; ANC Ͼ1 = time in days for neutrophil count Ͼ1 × 10 9 /l; RBC = units of blood transfused; DFS = disease-free survival (months); OS = overall survival (months); MUD = matched unrelated donor; DLC-B = diffuse large cell lymphoma (B cell); HD = Hodgkin's disease; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; CML = chronic myeloid leukemia; MM = multiple myeloma; PR = partial remission; CR = complete remission; R = relapse; AP = accelerated phase; CP = chronic phase; RT = radiotherapy; chemo = chemotherapy; 2nd SCT = second stem cell transplantation; DLI = donor lymphocyte infusion.
hemoglobin (range 0.06-1.5, normal 5.5-10.3). The incidence of G6PD deficiency in female CML patients was statistically higher than in female live-births (P = 0.004), but comparable with that in male live-births (P = 0.664) ( Table 2 ). The incidences in all other subgroups (male and female, donor and recipient, autologous and allogeneic BMT) were within expected statistical limits expected from background population. With appropriate avoidance of cotrimoxazole, there was no significant hemolysis (evident from polychromasia or bilirubinemia) or increased transfusion requirements. The G6PD status converted to the donor type in all but one allogeneic recipient. In patient 10, there was only partial correction of her G6PD status after SCT. Cytogenetic and RT-PCR analysis showed residual CML, and mixed chimerism was confirmed by cytogenetics and DNA microsatellite analysis (Figure 1 ). Ten months after SCT, she became G6PD deficient again, concomitant with a relapse of her CML.
Discussion
Glucose-6-phosphate dehydrogenase deficiency is Xlinked, and affects 2 to 5% of the male population in South East Asia and tropical Africa. It is the commonest cause of major hemolysis in HK. 8 The South China variants of G6PD point mutations mostly result in severe deficiencies. 9 The updated local incidence is 4.47% in males and 0.27% in females. 3 The absence of G6PD-deficient cases among female donors and non-CML patients, and the incidences of deficiency in male donors and recipients are all within statistically expected ranges. However, two female CML cases with G6PD deficiency were diagnosed. The erythroid lineage is part of the CML clone, which is a clonal multilineage stem cell disorder. 10 In females heterozygous for a mutated G6PD gene, if the CML stem cell arises in a cell with the normal allele randomly inactivated through X chromosome lyonization, the resulting clone including red cells will be G6PD deficient. Therefore, the incidence of G6PD deficiency in female CML patients might be expected to approach that in the male. Hence, attention should be drawn to a history of G6PD deficiency in a female CML patient, and screening of all marrow donor and recipients is mandatory in populations with known G6PD deficiency. 11 We also showed in this study that the monitoring of G6PD status may be a useful marker of chimerism. Monitoring of chimerism and residual disease after SCT is often performed with cytogenetics or PCR for known abnormalities. 6, 7, 12 Changes in red cells, however, may sometimes provide useful information. Alterations in major and minor blood groups may provide data on engraftment. 12 The monitoring of concurrent hemoglobinopathy and enzymopathy may also give useful ancillary data on erythroid engraftment. We have, for example, reported the loss of a thalassemic trait in a leukemic patient with a normal hemoglobin pattern, who had received an allogeneic SCT from a donor with thalassemic trait, to predate an ultimate disease relapse. 7 Similarly, the G6PD status may be useful in the investigation of donor/recipient chimerism, which in some situations may reflect disease relapse. Although less sensitive than chromosomes and molecular markers, red cell indices, hemoglobin pattern and G6PD screen can be performed frequently and inexpensively in regional clinics, and may give practical clues for picking up late occult relapses.
